EY Law advises Japanese group ROHTO on acquiring a majority stake in MoNo Chem-Pharm Products in Austria
The EY Law team, led by partner Mario Gall, is advising ROHTO in acquiring a majority stake in the Austrian Sigmapharm/MoNo chem-pharm group with comprehensive transaction advisory services. The deal is valued at approximately 30 million euros.
ROHTO Pharmaceutical will acquire 51% of the parent company of the Sigmapharm group, located in Austria. This investment aims to further expand Sigmapharm’s production capacities and distribution network and significantly strengthen ROHTO Pharmaceutical’s presence in the European market. ROHTO, based in Osaka, listed on the Tokyo Stock Exchange, specializes in the research, production, and distribution of over-the-counter (OTC) medicines, particularly in the area of eye drops.
“Congratulations to the ROHTO group on this investment in Austria. This deal once again highlights our expertise in international transaction advisory services in highly regulated business areas,” said Partner Mario Gall, Head of M&A Transaction department at EY Law.
The EY Law team advising ROHTO in the transaction includes: Lead-Attorney & Partner Mario Gall (M&A), Attorney Sonam Schima (M&A), Attorney Clara Messner-Kreuzbauer (M&A), Attorney David Konrath (Investment Control, Antitrust Law, and Compliance), Attorney Andreas Lopatka-Sint (Data Protection), Associate Laura Graf (M&A), Associate Paul Kness (M&A), and Associate Lukas Wandl (Data Protection). EY Law Japan is advising the pharma group on the Japanese side.
- All recent EY Law News
- More details to ROHTO Pharmaceutical
- Our service overview: M&A and Transaktionen
